

HHS Public Access

Curr Opin Psychol. Author manuscript; available in PMC 2020 December 01.

Published in final edited form as:

Author manuscript

Curr Opin Psychol. 2019 December; 30: 59-64. doi:10.1016/j.copsyc.2019.01.005.

Excessive discounting of delayed reinforcers as a trans-disease process

Warren K. Bickel^{a,b}, Liqa N. Athamneh^{a,c}, Julia C. Basso^b, Alexandra M. Mellis^{a,c}, William B. DeHart^a, William H. Craft^{a,c}, Derek Pope^a

^aAddiction Recovery Research Center, Virginia Tech Carilion Research Institute, VA, USA

^bCenter for Transformative Research on Health Behaviors, Virginia Tech Carilion Research, VA, USA

^cGraduate Program in Translational Biology, Medicine, and Health, Virginia Tech, VA, USA

Abstract

Delay discounting, or the process by which reinforcers lose value with delay to their receipt, has been identified as a trans-disease process underlying addiction, other disorders, and maladaptive health behaviors. Delay discounting has been identified as an endophenotype for multiple psychiatric disorders including substance use disorder, ADHD, and major depressive disorder, with this endophenotype being linked to deficits in dopaminergic and serotonergic neurotransmission. In addition, neuroanatomical and neurophysiological deficits in areas of the executive and impulsive systems have been associated with both steeper discounting and substance use disorders. Delay discounting constitutes a novel target for interventions to change health behaviors. A new theory, termed reinforcer pathology, has been developed uniting these findings and setting the stage for future research.

Delay discounting (DD), one of the most extensively studied behavioral economic measures, describes the decrease in a reward's value as a function of the delay to its receipt (see Box 1). All people discount delayed rewards to some extent, depending on the time frames examined. However, individuals with substance use disorder have significantly higher rates of DD [1**,2]. In one study, the delay at which \$1,000 had lost 50% of its value (e.g., ED50) for non-alcohol abusing controls was 166 months compared to just 23 months for individuals actively abusing alcohol [3]. DD has been suggested to serve as a behavioral marker of addiction at all stages of the process and has been predictive of treatment outcomes [2,4,5]. For example, among cigarette smokers, abstinence decreased by approximately 40% per one standard deviation increase in DD [4]. Similarly, among

Corresponding concerning this article should be addressed to Warren K. Bickel, Virginia Tech Carilion Research Institute, 2 Riverside Circle, Roanoke, VA, 24016 wkbickel@vtc.vt.edu.

Conflict of interest

None declared

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

alcohol-dependent smokers, risk of relapsing to smoking increased by 40–50% per one standard score increase on DD [6]. A prior review of DD [7] suggested that excessive discounting of delayed reinforcers is a trans-disease process not only in substance use disorder, but also in other disorders (e.g., obesity, pathological gambling, ADHD and schizophrenia) and maladaptive health behaviors (e.g., risky sexual behaviors). Importantly, the concept of trans-disease processes can allow for the insights from one disorder to be applied to another[8]. This short review will update the prior review by summarizing new findings including: the expansion of DD as a within-person determinant of multiple maladaptive health behaviors; the genetic and neural mechanisms undergirding DD; and new potential interventions and treatments based on influencing DD rates.

Expansion of the role of delay discounting in health behaviors

At the time of the prior review, the only health behaviors that had been specifically identified as correlated with DD were risky sexual behavior and needle sharing [7]. Recent work has expanded the range of health behaviors related to DD [17] to include type II diabetes [18], prediabetes, fast food consumption [19], texting while driving [20], poor medication adherence, seatbelt nonadherence, sunscreen non adherence, hypertension, visiting the dentist, and receiving the influenza vaccine [17].

The above research explored correlations between DD rates and engagement in health behaviors across individuals, but more recently, DD has been shown to predict engagement in multiple health behaviors within individuals. For example, Snider et al., [21]** asked cigarette smokers a wide range of questions regarding various health behaviors including financial, exercise, and eating behaviors. These questions were then grouped together into meaningful latent factors using structural equation modeling. Delay discounting significantly predicted these factors indicating that even within cigarette smokers, DD predicted other maladaptive behaviors. A recent follow-up has found similar results in obese individuals and healthy controls.

In a similar study, Sheffer et al. [22]** found that DD predicted a variety of health behaviors in cancer survivors. Delay discounting predicted weekly alcohol consumption, current cigarette smoking and other tobacco use, tanning booth use, and yearly visits to a primary care physician. These findings are powerful, given that these behaviors are particularly harmful for those with a history of cancer (and can play an etiological role in future cancer development).

Genetic markers of delay discounting

Decades of research has demonstrated similarity of neural mechanisms and high heritability of substance use disorders across drug classes [23]. Despite this, early investigations of candidate genes and genome wide associations have been unable to account for this high level of observed heritability. Given the diagnostic variability in substance use and other psychiatric disorders, investigative efforts have been redirected towards elucidating endophenotypes: heritable, neurobiological/behavioral mechanisms that undergird multiple disorders and provide a more precise biomarker for diagnosis [24].

A growing body of evidence supports DD as an endophenotype. Studies in humans and animals have demonstrated levels of heritability similar to substance use disorders (~50%), with elevated rates of DD seen in non-affected relatives of addicted individuals. These studies have shown that genetic polymorphisms association with altered dopaminergic signaling may underlie this endophenotype. For a review see [25]. In a seminal study, Sanchez-Roiges and colleagues performed a genome-wide association study of DD in over 23,000 individuals of European ancestry [26]*. Delay discounting was significantly associated with a polymorphism in a neuronal membrane protein (GPM6B), previously implicated in deficient serotonin transmission. Additionally, 12% of the variance in DD was accounted for by genotype and this genetic signature showed a positive correlation with ADHD, major depressive disorder, lifetime smoking, and BMI. Taken together, these findings show strong support for DD as an endophenotype for substance use disorders as

well as a trans-disease process underlying multiple psychiatric disorders and deleterious

Neural mechanisms underlying delay discounting and addiction

behavioral states.

The competing neurobehavioral decisions systems (CNDS) theory posits that healthy decision-making processes rely on a balance between two distinct neural systems termed the impulsive and executive systems [7,27,28]. The impulsive system, embodied in limbic and paralimbic brain structures (e.g., ventral striatum, hippocampus, cingulate cortex), regulates reward and motivation and is involved in the valuation of and decision for immediate reinforcers. The executive system, embodied in prefrontal cortical regions, regulates executive functions (e.g., attention, working memory, cognitive flexibility, and inhibitory control) and is involved in our ability to value future outcomes and delay reinforcement. As previously discussed, patients with substance use disorders demonstrate maladaptive decision-making processes and tend to choose immediate over delayed reinforcers. The CNDS theory posits that this behavioral imbalance stems from a regulatory imbalance between a hyperactive impulsive and a hypoactive executive system. Recent neurophysiological, neuroimaging, and neuromodulatory studies have lent support to this idea.

Electroencephalography (EEG) studies have revealed neurophysiological correlates of DD in populations with and without substance use disorders. In non-clinical populations, steeper DD is associated with lower levels of baseline brain activity in the prefrontal cortex, especially in the high beta frequency range (21.5–30 Hz) [29]. Others have found that non-deprived people with substance use disorders show decreased resting frontal, central, or whole brain delta (1.5–3.5 Hz), theta (4–7.5 Hz), and alpha (8–12.5 Hz) activity, with the lowest levels of activity predicting the highest levels of addictive behavior [30,31]. During DD task performance, the reward positivity signal (a positive-going event-related potential (ERP) that occurs approximately 250–350 ms post-stimulus presentation and is sensitive to gain instead of loss outcomes) is elicited following immediate but not delayed reinforcers, with a larger ERP amplitude seen in steeper discounters [32]. Together, these results indicate that decreased neural synchrony and efficiency of the cortical networks [33]as well as altered reward processing signaling, especially in frontal brain regions, may serve as a

neurological indication of altered decision-making properties and propensity for substance use disorders [34].

Structural and functional magnetic resonance imaging (MRI) studies have also helped us understand the neuroanatomical correlates of DD and substance use disorders. Using MRI, researchers have shown that steeper DD is associated with lower cortical [35] and higher subcortical [36]gray matter volume, with similar neuroanatomical findings shown in addicted populations [37]. During resting state fMRI, a large-scale brain network known as the default mode network (DMN) is activated, which is involved in self-referential thinking as well as the ability to remember the past and think about the future. New research has revealed that a greater disorder of activity in the DMN is related to steeper DD [38], and DMN functional connectivity is dysregulated in substance use disorders [39,40]. fMRI studies have revealed that during the DD task, healthy individuals show heightened activation and functional connection in areas of the executive system during choices associated with delayed reinforcers [41,42]. However, individuals with substance use disorders show decreased activity in areas of the executive system and heightened activity in areas of the impulsive system [43,44]. Collectively, these studies suggest that individuals with high levels of DD and/or substance use disorders may show neuroanatomical deficits, as well as differences in functional activation and connectivity at rest and during reward processing in both executive and impulsive systems.

Novel interventions to target delay discounting

Several interventions are now targeting DD as a means to positively affect associated disorders, and we will briefly address the few most promising (neuromodulation and episodic future thinking). However, note that other research has investigated working memory training, mindfulness, transcranial direct current stimulation (TCDS) and others as potential interventions [45,46].

Neuromodulatory methods may shed unique insight into both the neural substrates underlying discounting itself and the role of DD in health and disorders. Specifically, transcranial magnetic stimulation (TMS) is a non-invasive form of neuromodulation, which may be used to either potentiate or decrease activity in cortical regions using electromagnetic fields. By repeated applications of TMS (a procedure known as rTMS), Cho and colleagues [47] were able to experimentally implicate the medial prefrontal cortex (mPFC) in DD. rTMS to the mPFC (compared to the vernex) attenuated both DD rates and striatal dopamine release, supporting a dual-decision model for the emergence of DD from an interaction between executive and impulsive regions [48]. These neuromodulatory approaches have also been applied therapeutically, as a novel intervention. Recently, Sheffer and colleagues [22]** applied rTMS to another prefrontal, executive region implicated in DD, the dorsolateral prefrontal cortex (dlPFC), in a double-blind, randomized controlled trial of 29 smokers. Active rTMS both reduced DD and enhanced the effects of a self-help smoking cessation program, increasing abstinence and reducing relapse at 12 weeks. This treatment had both high acceptability and promising efficacy, suggesting that neuromodulation, like other interventions targeting DD, has promising translational potential in addiction treatment.

Another successful approach to increasing the valuation of the future is episodic future thinking (EFT), derived from the science of prospection. Episodic future thinking entails vividly imagining positive, personal future events, and has been shown to reduce DD rates [49]*. Presentation of these episodic future events has been shown to engage the hippocampus and amygdala and enhance prefrontal-mediotemporal interactions [49]*. Most importantly, EFT has reduced excessive DD in several disorders (e.g., overweight/obesity, smoking, alcohol use disorder, and gambling). New fMRI research has revealed that EFT enhances functional connectivity between the ventromedial PFC and the ventral striatum in both healthy individuals and pathological gamblers, which the authors suggest is a possible mechanism driving the EFT-induced reduction in DD [50]. This manipulation has remarkable potential as a therapeutic intervention.

Discussion

Here, we updated the findings regarding DD as a trans-disease process. Specifically, new evidence supports the expansion of this concept to include multiple health behaviors, both between and within individuals. Moreover, methodological advances permit the rapid assessment of DD perhaps heralding future applications in a wider array of studies. Since the first report, scientific investigations have identified both genetic and neural substrates of DD, clarifying this measure's role as an endophenotype of multiple behaviors. Not surprisingly, given these results, interventions are being devised to modulate DD (Figure 1).

Those disorders associated with excessive consumption of brief, intense reinforcers are commonly relapsing. Importantly, the hyperbolic function of DD predicts preference reversals that may undergird this relapse. For example, one might prefer the delayed benefits of weight loss, and would intend to decline dessert. However, when the dessert tray is presented, the preference reverses. More formally, a larger and *more* delayed reinforcer may initially be preferred when considered from afar; however, as both reinforcers become more proximal, the smaller, sooner reinforcer's value increases.

One consequence of the manipulation of DD has been the examination of its effects on other measures, in particular the valuation of brief, intense reinforcers (e.g., drugs, food). One contemporary theory of addiction, reinforcer pathology, has emerged from this line of study [51–53]. Specifically, reinforcer pathology proposes that DD measures the temporal window over which reinforcers are integrated, which determines the relative value of substance-related and/or prosocial reinforcers [51,52*,53]. For example, studies have found that increasing or decreasing the temporal window (reducing and increasing DD) has reduced or increased valuation of brief, intense reinforcers, including alcohol [54]*, cigarettes [55], and food [16*,56]. As a result, DD should be further examined as an etiologic process in the development of these disorders. If the results of those explorations are robust, the stage may be set for novel theoretical understanding of these disorders and new interventions to treat them.

Acknowledgments

Funding: This work was supported by the National Institute of Health (grant numbers R01DA034755, R01AA021529) and the National Institutes of Health (NIH) Science of Behavior Change Common Fund Program

through an award administered by the National Institute of Diabetes and Digestive and Kidney Diseases (1UH3DK109543).

References

- [1]. Amlung M, Vedelago L, Acker J, Balodis I, Mackillop J: Steep Delay Discounting and Addictive Behavior: A Meta-Analysis of Continuous Associations. Addiction 2016, doi:10.1111/add. 13535.** This Meta-analysis provides an impartially comprehensive examination of delay discounting in cross-sectional addiction studies using continuous designs. The study aggregates the diverse findings in the literature to investigate the extent to which delay discounting is associated with addiction-related variables (e.g., psychoactive drugs and gambling behavior), and with indices of engagement in addictive behaviors (i.e., quantity-frequency) or level of clinical severity across studies. Findings from 64 studies (138 effect sizes) indicate a robust association between delayed reward discounting (across type of addictive behaviors. Importantly, the magnitude of this relation did not significantly differ across the types of addictive behavior examined supporting delay discounting as a trans-disease process in addiction.
- [2]. Bickel WK, Koffarnus MN, Moody L, Wilson AG: The behavioral- and neuro-economic process of temporal discounting: A candidate behavioral marker of addiction. Neuropharmacology 2014, 76 Pt B:518–527. [PubMed: 23806805]
- [3]. Petry NM. Delay discounting of money and alcohol in actively using alcoholics, currently abstinent alcoholics, and controls. Psychopharmacology 2001, 154: 243–250 [PubMed: 11351931]
- [4]. Sheffer C, Mackillop J, McGeary J, Landes R, Carter L, Yi R, Jones B, Christensen D, Stitzer M, Jackson L, et al.: Delay discounting, locus of control, and cognitive impulsiveness independently predict tobacco dependence treatment outcomes in a highly dependent, lower socioeconomic group of smokers. Am J Addict 2012, 21:221–232. [PubMed: 22494224]
- [5]. Washio Y, Higgins ST, Heil SH, McKerchar TL, Badger GJ, Skelly JM, Dantona RL: Delay discounting is associated with treatment response among cocaine-dependent outpatients. Exp Clin Psychopharmacol 2011, 19:243–248. [PubMed: 21517195]
- [6]. MacKillop J, Kahler CW: Delayed reward discounting predicts treatment response for heavy drinkers receiving smoking cessation treatment. Drug Alcohol Depend 2009, 104:197–203. [PubMed: 19570621]
- [7]. Bickel WK, Jarmolowicz DP, Mueller ET, Koffarnus MN, Gatchalian KM: Excessive discounting of delayed reinforcers as a trans-disease process contributing to addiction and other diseaserelated vulnerabilities: emerging evidence. Pharmacol Ther 2012, 134:287–297. [PubMed: 22387232]
- [8]. Bickel WK, Mueller ET: Toward the Study of Trans-Disease Processes: A Novel Approach With Special Reference to the Study of Co-morbidity. J Dual Diagn 2009, 5:131–138. [PubMed: 20182654]
- [9]. Mazur JE: An adjusting procedure for studying delayed reinforcement. Commons ML; Mazur JE; Nevin JA 1987,
- [10]. Du W, Green L, Myerson J: Cross-cultural comparisons of discounting delayed and probabilistic rewards. Psychol Rec 2002,
- [11]. Odum AL, Madden GJ, Bickel WK: Discounting of delayed health gains and losses by current, never- and ex-smokers of cigarettes. Nicotine Tob Res 2002, 4:295–303. [PubMed: 12215238]
- [12]. Odum AL, Baumann AAL: Cigarette smokers show steeper discounting of both food and cigarettes than money. Drug Alcohol Depend 2007, 91:293–296. [PubMed: 17720334]
- [13]. Koffarnus MN, Bickel WK: A 5-trial adjusting delay discounting task: accurate discount rates in less than one minute. Exp Clin Psychopharmacol 2014, 22:222–228. [PubMed: 24708144]
- [14]. Bickel WK, Landes RD, Christensen DR, Jackson L, Jones BA, Kurth-Nelson Z, Redish AD: Single- and cross-commodity discounting among cocaine addicts: the commodity and its temporal location determine discounting rate. Psychopharmacology 2011, 217:177–187. [PubMed: 21487658]

- [15]. Moody LN, Tegge AN, Bickel WK: Cross-commodity delay discounting of alcohol and money in alcohol users. Psychol Rec 2017, 67:285–292. [PubMed: 29056767] * The study extends upon previous work (on smoking and cocaine) to assess how alcohol users value alcohol when compared with money across same- and cross-commodity delay discounting choice conditions. Using data collected online via Amazon Mechanical Turk, the study showed that alcohol now, money later was discounted the least and money now, alcohol later was discounted the most regardless of alcohol use severity. Moreover, in the same-commodity tasks the study did not detect a difference in discounting in the money now, money later condition between varying degrees of alcohol use. However, a steeper rate of discounting was reported when the commodity is alcohol as opposed to money.
- [16]. Mellis AM, Athamneh LN, Stein JS, Sze YY, Epstein LH, Bickel WK: Less is more: Negative income shock increases immediate preference in cross commodity discounting and food demand. Appetite 2018, 129:155–161. [PubMed: 29959952] * The study examines how a negative income shock may affect both monetary and food reinforcement in 120 obese participants through a reinforcer pathology framework. The study examined delay discounting of all combinations of immediate and delayed money and fast food and hypothetical purchasing tasks of both fast food and a control commodity not associated with reinforcer pathology (bottled water). Using data collected online via Amazon Mechanical Turk, the study indicated higher discounting rates and intensity of demand for fast food among the group presented with an income shock compared to controls, representing a high-risk state for negative health behavior in obesity.
- [17]. Story GW, Vlaev I, Seymour B, Darzi A, Dolan RJ: Does temporal discounting explain unhealthy behavior? A systematic review and reinforcement learning perspective. Front Behav Neurosci 2014, 8:76. [PubMed: 24659960]
- [18]. Lebeau G, Consoli SM, Le Bouc R, Sola-Gazagnes A, Hartemann A, Simon D, Reach G, Altman J-J, Pessiglione M, Limosin F, et al.: Delay discounting of gains and losses, glycemic control and therapeutic adherence in type 2 diabetes. Behav Processes 2016, 132:42–48. [PubMed: 27663668]
- [19]. Garza KB, Ding M, Owensby JK, Zizza CA: Impulsivity and Fast-Food Consumption: A CrossSectional Study among Working Adults. J Acad Nutr Diet 2016, 116:61–68. [PubMed: 26095434]
- [20]. Hayashi Y, Miller K, Foreman AM, Wirth O: A behavioral economic analysis of texting while driving: Delay discounting processes. Accid Anal Prev 2016, 97:132–140. [PubMed: 27614547]
- [21]. Snider SE, DeHart WB, Epstein LH, Bickel WK: Does delay discounting predict maladaptive health and financial behaviors in smokers? Health Psychol 2018, doi:10.1037/hea0000695.** The authors used structural equation modelling to interrogate the relationship between health and financial planning behaviors and DD. These behaviors grouped into highly significantly latent factors of "Drug Use," "Finances," "Fitness," "Food," "Health," "Household Savings," "Personal Development," and "Safe Driving." Interestingly, independent of smoking status, delay discounting significantly predicted engagement in all but one of these factors.
- [22]. Sheffer CE, Bickel WK, Brandon TH, Franck CT, Deen D, Panissidi L, Abdali SA, Pittman JC, Lunden SE, Prashad N, et al.: Preventing relapse to smoking with transcranial magnetic stimulation: Feasibility and potential efficacy. Drug Alcohol Depend 2018, 182:8–18. [PubMed: 29120861] ** The relations between delay discounting and years since diagnosis and 10 health behaviors (e.g., alcohol use, cigarette smoking, tobacco use, tanning booth use, adherence to annual primary care visits) were examined among 1001 cancer survivors. Specifically, DD rates were positively associated with alcohol consumption, cigarette smoking, other tobacco use, tanning booth use, and negatively associated with adherence to annual primary care visits. These results suggest that, among cancer survivors, DD rate may be a promising therapeutic target for new interventions that aim to improve multiple health behaviors.
- [23]. Goldman D, Oroszi G, Ducci F: The genetics of addictions: uncovering the genes. Nat Rev Genet 2005, 6:521–532. [PubMed: 15995696]
- [24]. Insel TR: The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry 2014, 171:395–397. [PubMed: 24687194]
- [25]. Gray JC, MacKillop J: Impulsive delayed reward discounting as a genetically-influenced target for drug abuse prevention: a critical evaluation. Front Psychol 2015, 6:1104. [PubMed: 26388788]

- [26]. Sanchez-Roige S, Fontanillas P, Elson SL, Pandit A, Schmidt EM, Foerster JR, Abecasis GR, Gray JC, de Wit H, Davis LK, et al.: Genome-wide association study of delay discounting in 23,217 adult research participants of European ancestry. Nat Neurosci 2018, 21:16–18. [PubMed: 29230059] ** This genome-wide association study interrogated correlates of delay discounting using data from 23,127 participants of European ancestry. The study reported significant association between DD and the single-nucleotide polymorphism rs6528024 (P = 2.40 Å~ 10–8) located in an intron of the gene GPM6B. In addition, the study showed that the genetic signature of DD overlapped with smoking, cognition, personality, body weight, ADHD, schizophrenia, and major depression. Moreover, the study reported that 12% of the variance in DD was accounted for by genotype.
- [27]. McClure SM, Laibson DI, Loewenstein G, Cohen JD: Separate neural systems value immediate and delayed monetary rewards. Science 2004, 306:503–507. [PubMed: 15486304]
- [28]. Frost R, McNaughton N: The neural basis of delay discounting: A review and preliminary model. Neurosci Biobehav Rev 2017, 79:48–65. [PubMed: 28465167]
- [29]. Gianotti LRR, Figner B, Ebstein RP, Knoch D: Why Some People Discount More than Others: Baseline Activation in the Dorsal PFC Mediates the Link between COMT Genotype and Impatient Choice. Front Neurosci 2012, 6:54. [PubMed: 22586360]
- [30]. Lee JY, Park SM, Kim YJ, Kim DJ, Choi S-W, Kwon JS, Choi J-S: Resting-state EEG activity related to impulsivity in gambling disorder. J Behav Addict 2017, 6:387–395. [PubMed: 28856896]
- [31]. Rass O, Ahn W-Y, O'Donnell BF: Resting-state EEG, impulsiveness, and personality in daily and nondaily smokers. Clin Neurophysiol 2016, 127:409–418. [PubMed: 26051750]
- [32]. Cherniawsky AS, Holroyd CB: High temporal discounters overvalue immediate rewards rather than undervalue future rewards: an event-related brain potential study. Cogn Affect Behav Neurosci 2013, 13:36–45. [PubMed: 22983745]
- [33]. Su S, Yu D, Cheng J, Chen Y, Zhang X, Guan Y, Li Y, Bi Y, Xue T, Lu X, et al.: Decreased Global Network Efficiency in Young Male Smoker: An EEG Study during the Resting State. Front Psychol 2017, 8:1605. [PubMed: 28951727]
- [34]. Kwako LE, Bickel WK, Goldman D: Addiction Biomarkers: Dimensional Approaches to Understanding Addiction. Trends Mol Med 2018, 24:121–128. [PubMed: 29307501]
- [35]. Owens MM, Gray JC, Amlung MT, Oshri A, Sweet LH, MacKillop J: Neuroanatomical foundations of delayed reward discounting decision making. Neuroimage 2017, 161:261–270. [PubMed: 28843539]
- [36]. Tschernegg M, Pletzer B, Schwartenbeck P, Ludersdorfer P, Hoffmann U, Kronbichler M: Impulsivity relates to striatal gray matter volumes in humans: evidence from a delay discounting paradigm. Front Hum Neurosci 2015, 9:384. [PubMed: 26190993]
- [37]. Suckling J, Nestor LJ: The neurobiology of addiction: the perspective from magnetic resonance imaging present and future. Addiction 2017, 112:360–369. [PubMed: 27452960]
- [38]. Chen Z, Guo Y, Feng T: Delay discounting is predicted by scale-free dynamics of default mode network and salience network. Neuroscience 2017, 362:219–227. [PubMed: 28844008]
- [39]. Liang X, He Y, Salmeron BJ, Gu H, Stein EA, Yang Y: Interactions between the salience and defaultmode networks are disrupted in cocaine addiction. J Neurosci 2015, 35:8081–8090. [PubMed: 26019326]
- [40]. Zhu X, Cortes CR, Mathur K, Tomasi D, Momenan R: Model-free functional connectivity and impulsivity correlates of alcohol dependence: a resting-state study. Addict Biol 2017, 22:206– 217. [PubMed: 26040546]
- [41]. Wesley MJ, Bickel WK: Remember the future II: meta-analyses and functional overlap of working memory and delay discounting. Biol Psychiatry 2014, 75:435–448. [PubMed: 24041504]
- [42]. Koffarnus MN, Deshpande HU, Lisinski JM, Eklund A, Bickel WK, LaConte SM: An adaptive, individualized fMRI delay discounting procedure to increase flexibility and optimize scanner time. Neuroimage 2017, 161:56–66. [PubMed: 28803942]
- [43]. Lim AC, Cservenka A, Ray LA: Effects of Alcohol Dependence Severity on Neural Correlates of Delay Discounting. Alcohol Alcohol 2017, 52:506–515. [PubMed: 28340213]

- [44]. Wang Y, Hu Y, Xu J, Zhou H, Lin X, Du X, Dong G: Dysfunctional Prefrontal Function Is Associated with Impulsivity in People with Internet Gaming Disorder during a Delay Discounting Task. Front Psychiatry 2017, 8:287. [PubMed: 29326612]
- [45]. Verdejo-García A, Alcázar-Córcoles MA, Albein-Urios N: Neuropsychological Interventions for Decision-Making in Addiction: a Systematic Review. Neuropsychol Rev 2018, doi:10.1007/ s11065-018-9384-6.
- [46]. Rung JM, Madden GJ: Experimental reductions of delay discounting and impulsive choice: A systematic review and meta-analysis. J Exp Psychol Gen 2018, 147:1349–1381. [PubMed: 30148386]
- [47]. Cho SS, Koshimori Y, Aminian K, Obeso I, Rusjan P, Lang AE, Daskalakis ZJ, Houle S, Strafella AP: Investing in the future: stimulation of the medial prefrontal cortex reduces discounting of delayed rewards. Neuropsychopharmacology 2015, 40:546–553. [PubMed: 25168685]
- [48]. Bickel WK, Miller ML, Yi R, Kowal BP, Lindquist DM, Pitcock JA: Behavioral and neuroeconomics of drug addiction: competing neural systems and temporal discounting processes. Drug Alcohol Depend 2007, 90 Suppl 1:S85–91. [PubMed: 17101239]
- [49]. Peters J, Büchel C: Episodic future thinking reduces reward delay discounting through an enhancement of prefrontal-mediotemporal interactions. Neuron 2010, 66:138–148. [PubMed: 20399735] * In two separate studies, Peters and Büchel revealed a mechanism through which prospection networks and neural decision-making can connect to induce future-minded choice behavior. The study used functional magnetic resonance imaging (fMRI) and neural coupling analyses to show that episodic future thinking (EFT) reduces DD through a modulation of functional coupling of anterior cingulate and hippocampus/amygdala.
- [50]. Wiehler A, Petzschner FH, Stephan KE, Peters J: Episodic Tags Enhance Striatal Valuation Signals during Temporal Discounting in pathological Gamblers. eNeuro 2017, 4.
- [51]. Jarmolowicz DP, Reed DD, DiGennaro Reed FD, Bickel WK: The Behavioral and Neuroeconomics of Reinforcer Pathologies: Implications for Managerial and Health Decision Making. Manage Decis Econ 2016, 37:274–293.
- [52]. Bickel WK, Stein JS, Moody LN, Snider SE, Mellis AM, Quisenberry AJ: Toward Narrative Theory: Interventions for Reinforcer Pathology in Health Behavior. Nebr Symp Motiv 2017, 64:227–267. [PubMed: 30351565] * This chapter summarizes the extant evidence on DD as a measure of impulsivity, and describes reinforcer pathology theory (i.e. the interaction between DD and reinforcer valuation). The chapter summaries evidence suggesting that reinforcer pathology is related to several disorders, including drug abuse and obesity. The authors also introduce for the first time the methods of narrative theory, a framework for intervention development which harnesses humans' unique sensitivity to language and storytelling. The chapter presents evidence that narratives can alter DD.
- [53]. Lemley SM, Kaplan BA, Reed DD, Darden AC, Jarmolowicz DP: Reinforcer pathologies: Predicting alcohol related problems in college drinking men and women. Drug Alcohol Depend 2016, 167:57–66. [PubMed: 27515726]
- [54]. Snider SE, LaConte SM, Bickel WK: Episodic Future Thinking: Expansion of the Temporal Window in Individuals with Alcohol Dependence. Alcohol Clin Exp Res 2016, 40:1558–1566.
 [PubMed: 27246691] * The study examines the effect of engaging in episodic future thinking (EFT) or episodic recent thinking (ERT) on discounting rates and alcohol purchasing behavior among 55 alcohol dependent individuals. The study findings of a longer temporal window and a lower demand intensity for alcohol following engagement with EFT were consistent with findings of other EFT studies in other populations (e.g., smokers and obese participants). However, interestingly, using correlational analyses the current study suggests that the effect of EFT might be negatively associated with the severity of alcohol abuse (AUDIT scores) where those with lower alcohol severity being readily influenced by EFT compared to those with more severe dependence.
- [55]. Stein JS, Wilson AG, Koffarnus MN, Daniel TO, Epstein LH, Bickel WK: Unstuck in time: episodic future thinking reduces delay discounting and cigarette smoking. Psychopharmacology 2016, 233:3771–3778. [PubMed: 27553824]
- [56]. Dassen FCM, Jansen A, Nederkoorn C, Houben K: Focus on the future: Episodic future thinking reduces discount rate and snacking. Appetite 2016, 96:327–332. [PubMed: 26431684]

Highlights

- Delay discounting (DD) indicates choice between smaller, sooner and larger, later reinforcers.
- DD modulates the risk of substance use disorder, other disorders, and maladaptive health behaviors.
- DD predicts engagement in multiple health behaviors between and within individuals.
- Novel interventions targeting DD may positively affect associated disorders and behaviors.

Box 1.

Measuring Delay Discounting

Delay discounting procedures present choices between smaller, sooner and larger, later reinforcers of varying magnitudes and at varying delays (e.g., \$50 now versus \$100 in 3 months). DD is generally assumed to be hyperbolic, with the subjective value of a reinforcer declining rapidly at short delays before reaching a relative plateau [9]. Adjusting-amount DD procedures [e.g., 10] present choices between immediate and delayed reinforcers (often monetary, although sometimes other commodities such as health outcomes or drugs [11,12]) to determine points of indifference between these options at each delay. As a result, these methods require a substantial number of trials to obtain indifference points across a number of delays. To more rapidly assess DD, an adjusting-delay DD procedure was developed requiring only five trials and less than a minute to obtain DD rates [see 13 for data and justification of these procedures]. However, the adjusting-delay task is designed to assess DD of a single commodity over varying delays. Most real-world choices are between different reinforcers available following different delays (e.g., fast food now or weight loss later). To address these choices, a cross-commodity discounting procedure was developed to examine the interaction among intertemporal choice and reinforcer type (initially, cocaine or money) [14]. Since the introduction of the first cross-commodity study, several other reinforcer combinations (e.g., sex, fast food, and weight loss) have been assessed using this procedure $[15^*, 16^*]$. These cross-commodity procedures allow for dissociation of the relative discounting and utility functions for each reinforcer being examined.




Figure 1.

Schematic representation of delay discounting (DD) as a trans-disease process. Genetic, neural, environmental and other factors can increase DD rates and therefore modulate the risk of substance use disorder (e.g., AUD), other disorders (e.g., obesity and schizophrenia) as well as a maladaptive health behavior (e.g., poor medication adherence and texting while driving). Importantly, many of the risks modulated by DD (e.g., AUD, and obesity) have the capacity to feed-back and increase the steepness of DD rates. DD's ability to predict engagement in multiple health behaviors has been shown not only across individuals, but more recently, within individuals as well. Promising novel interventions (e.g., TMS and EFT) are now targeting DD as a means to positively affect associated disorders and behaviors.